

CONTENTS

SUMMARY	v
ZUSAMMENFASSUNG	ix
ABBREVIATIONS	xiii
CHAPTER 1: General Introduction	1
1.1. Targeted radiopharmaceuticals for cancer diagnosis and therapy	2
1.2. Dose estimations	4
1.3. Targeted radiopharmaceuticals.....	7
1.3.1. Radiolabeled somatostatin analogs	7
1.3.2. Radiolabeled folic acid conjugates	8
1.4. Off-target toxicity during targeted radionuclide therapy.....	10
1.4.1. Bone marrow toxicity	11
1.4.2. Radionephrotoxicity.....	11
1.5. Strategies for improving targeted radionuclide therapy.....	12
1.5.1. Reduction of renal toxicity.....	14
1.5.2. Improvement of anti-tumor effect	15
1.6. Aim of the thesis	15
CHAPTER 2: Folate Receptor-Targeted Radionuclide Therapy: Preclinical	
Investigation of Anti-Tumor Effects and Potential Radionephropathy	17
2.1. Introduction.....	18
2.2. Materials and methods	19
2.2.1. Cell culture	19
2.2.2. Preparation of ¹⁷⁷ Lu-EC0800 and ¹⁷⁷ Lu-cm09	20
2.2.3. Animal studies.....	20
2.2.4. Statistical analysis	24
2.3. Results.....	24
2.3.1. Biodistribution of ¹⁷⁷ Lu-EC0800 and ¹⁷⁷ Lu-cm09 and dose estimations	24
2.3.2. Therapy study in KB tumor-bearing mice	27
2.3.3. Long-term damage to the kidneys	29
2.3.4. Non-renal side effects	36

2.3.5. Monitoring of body weight and survival	37
2.4. Discussion	38
2.5. Conclusion	41
CHAPTER 3: Impact of Amifostine and Captopril on the Tissue Distribution and Renal Side Effects of Therapeutic Radiofolates	43
3.1. Introduction	44
3.2. Materials and methods	47
3.2.1. Cell culture	47
3.2.2. Preparation of captopril and amifostine	47
3.2.3. Preparation of ¹⁷⁷ Lu-cm09 and ¹⁷⁷ Lu-cm10	47
3.2.4. Animal studies	49
3.2.5. Statistical analysis	52
3.3. Results	52
3.3.1. Tissue distribution of radiofolates after co-application of captopril	52
3.3.2. Tissue distribution of radiofolates after co-application of amifostine	54
3.3.3. Renal side effects after co-treatment with ¹⁷⁷ Lu-cm09 and amifostine	54
3.4. Discussion	57
3.5. Conclusion	59
CHAPTER 4: A Comparative Study about Renal Toxic Side Effects after α- and β-Therapy	61
4.1. Introduction	62
4.2. Materials and methods	63
4.2.1. Radionuclides	63
4.2.2. Preparation of ¹⁴⁹ Tb-cm09 and ¹⁶¹ Tb-cm09	64
4.2.3. Animal studies	64
4.2.4. Statistical analysis	67
4.3. Results	67
4.3.1. Radiosynthesis of ¹⁴⁹ Tb-cm09 and ¹⁶¹ Tb-cm09	67
4.3.2. Renal dose estimations for ¹⁴⁹ Tb-cm09 and ¹⁶¹ Tb-cm09	67
4.3.3. Long-term damage to the kidneys	68
4.3.4. Non-renal side effects	74
4.4. Discussion	76
4.5. Conclusion	77

CHAPTER 5: Combination of Glucocorticoids with Therapeutic

Radiopharmaceuticals: Beneficial Effects or Contraindication?	79
5.1. Introduction	80
5.2. Materials and methods	82
5.2.1. Reagents	82
5.2.2. Cell culture	83
5.2.3. Radiosynthesis	83
5.2.4. In vitro studies	84
5.2.5. Animal studies	85
5.2.6. Statistical analysis	87
5.3. Results	88
5.3.1. Impact of GCs on cellular uptake of radiopharmaceuticals	88
5.3.2. Effect of GCs on cancer cell viability	89
5.3.3. In vitro radioresistance after co-incubation with GCs	90
5.3.4. Tissue distribution of ¹⁷⁷ Lu-cm10 after co-treatment with dexamethasone ..	92
5.3.5. Anti-tumor effect of ¹⁷⁷ Lu-cm10 combined with dexamethasone	93
5.4. Discussion	95
5.5. Conclusion	97

CHAPTER 6: Are Auger Electrons Suitable for Targeted Radionuclide Therapy?

- First In Vitro Results with Nuclear-Localizing Peptides	99
6.1. Introduction	100
6.2. Material and methods	102
6.2.1. Radiosynthesis	102
6.2.2. Cell culture	103
6.2.3. In vitro studies	104
6.2.4. Animal studies	108
6.2.5. Statistical analysis	109
6.3. Results	109
6.3.1. Binding affinity of ¹⁷⁷ Lu-DOTATOC and ¹⁷⁷ Lu-MG136	109
6.3.2. Cellular retention of ¹⁷⁷ Lu-DOTATOC and ¹⁷⁷ Lu-MG136	109
6.3.3. Nuclear uptake of ¹⁷⁷ Lu-DOTATOC and ¹⁷⁷ Lu-MG136	110
6.3.4. Cytotoxicity of ¹⁷⁷ Lu-DOTATOC and ¹⁷⁷ Lu-MG136	110
6.3.5. Tissue distribution of ¹⁷⁷ Lu-DOTATOC and ¹⁷⁷ Lu-MG136	112

6.4. Discussion.....	115
6.5. Conclusion	117
CHAPTER 7: Conclusion and Outlook.....	119
BIBLIOGRAPHY	125
CURRICULUM VITAE	139